Search
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalAn oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. … It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Synonyms: L-Glutamin, L-GlutamineInternational brands: L-Glutamine PowerMacimorelin
go.drugbank.com/drugs/DB13074ApprovedMore specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels … Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone
Categories: Tests for Pituitary FunctionGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSulfametopyrazine
go.drugbank.com/drugs/DB00664ApprovedWithdrawnLong-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseChlorobutanol
go.drugbank.com/drugs/DB11386ApprovedVet approvedWithdrawnChlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746]. … Chlorobutanol is a common detergent preservative in eye drops and other ophthalmic therapeutic formulations [A32744].
Mixtures: Gouttes Pour Mal D'oreillesCategories: Compounds used in a research, industrial, or household settingCilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalIt is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States. … It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.
Categories: Agents Acting on the Renin-Angiotensin System, Antihypertensive Agents Indicated for HypertensionAsparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalAsparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia … For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].
Synonyms: Asparaginase (E. coli), E. coli AsparaginaseProducts: LEUNASE FOR INJECTION 10,000 iu/vialRezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigational[A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. … Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily.
Synonyms: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Canagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897].
Categories: Drugs Used in Diabetes